The epidemiology of prostate cancer
Introduction
Prostate cancer is the most common cancer and the second most common cause of cancer-related death amongst men in the Americas, Europe and Australia. The role of imaging in prostate cancer is continuously evolving in parallel with increasing understanding of the underlying biological heterogeneity which characterises the disease. Functional and metabolic imaging techniques are gaining importance as the emphasis in management has shifted from structural tumour detection to accurate risk-stratification at the time of diagnosis and post-treatment follow-up. Several imaging modalities are considered the key vehicles for translating molecular biology approaches into the clinical realm in prostate cancer. Technological advances in magnetic resonance imaging (MRI), positron-emission tomography (PET), optical imaging and Cerenkov imaging offer the possibility to directly visualise molecular interactions, something not achievable with standard imaging techniques [1] . These advances include the use of activatable imaging agents, which comprise the most complex of all imaging probes [2] . Through interaction with their target, activatable probes undergo a transformation that leads to a change in the emitted signal (usually, it is switched 'on' or 'off'). Thus, in contrast to targeted agents, which provide information merely about the physical presence of the target, activatable agents (often called 'smart' sensors) deliver information on the biological activity of their target [2] . Activatable agents have been devised predominantly for optical imaging applications but also for MRI. Since radioactive decay is a physical process that cannot be modified, activatable radioactive agents have long been considered impossible. However, use of the radioactive decay signal of Cerenkov light [3] may soon open the door for radiotracer-based activatable imaging agents.
Identification of a suitable molecular target
Designing imaging probes for advanced prostate cancer imaging can be challenging and involves meeting several key requirements: (1) identifying a suitable target specifically associated with prostate cancer and finding an appropriate ligand that will bind to it with high specificity; (2) labelling this ligand with a label suitable for the preferred imaging modality, which should allow for clinical translation. To find targets and ligands, various approaches can be used, including gene expression profiling and exploration of libraries. The design of the imaging probe must also take into consideration barriers it might encounter during its journey to its target. For prostate cancer, several targets have been identified, which are discussed below.
Androgen receptor (AR) imaging
Androgen deprivation therapy has played a role in the management of patients with advanced prostate cancer for over half a century [4] .
Most patients with metastatic prostate cancer respond to androgen deprivation (pharmacological or surgical); however, almost invariably this is followed by progression to 'castration-resistant' disease which occurs due to 'sensitising' or 'bypassing' of the androgen receptor (AR) pathway. The AR is a ligand-dependent transcription activator which plays a key role in cell differentiation and cell proliferation [5] . The treatment of castration-resistant prostate cancer has been revolutionised in recent years by the introduction of novel therapeutic agents targeting the AR (e.g., enzalutamide) [6] .
The distribution of anatomical sites where the AR is overexpressed can be imaged using the PET agent 16β-[ 18 F]fluoro-5α-dihydrotestosterone ( 18 F-FDHT) [7] [8] [9] . The differential overexpression of AR has been shown in studies comparing 18 F-FDHT and 18 F-FDG in men with castrationresistant prostate cancer which have identified different 'phenotypes' amongst these patients, including those with lesions demonstrating preferential tracer accumulation on FDHT PET (AR-predominant), preferential accumulation on FDG PET (glycolysis predominant) and mixed (i.e., uptake on both FDHT and FDG PET) phenotypes (Fig. 1) [10, 11] . A recent study evaluated the associations between morphological CT patterns, glycolytic activity and AR expression on PET and found that the numbers of bone lesions on CT, FDG PET and FDHT PET, as well as the intensity of FDHT uptake, are significantly associated with overall survival [11] . 18 F-FDHT could also have a potential role as a pharmacodynamic marker of drug targeting. One study reported that enzalutamide (AR receptor antagonist) induced 18 F-FDHT uptake changes in metastatic lesions could be considered a surrogate marker for adequate 'targeting' of prostate cancer metastases with AR overexpression [6] .
Prostate-specific membrane antigen (PSMA) Prostate-specific membrane antigen (PSMA) is probably the most prominent prostate cancer-associated antigen. It is a dimeric Type II integral membrane glycoprotein, highly expressed on prostate cancer cells [12] . Higher PSMA levels are seen in metastatic and higher-grade prostate cancer [13] . High levels of PSMA expression correlate significantly with early biochemical recurrence in surgically treated prostate cancer and also with tumour stage, Gleason grade and preoperative PSA and HER2 expression (P<0.0001 each) [14] . It has also been shown that the level of PSMA expression associated with benign prostatic hyperplasia (BPH) is lower than that associated with normal prostate and significantly lower than that associated with prostate cancer [15, 16] . Therefore BPH is not expected to substantially interfere with any PSMA-based methods of characterising prostatic tissue (e.g., as benign or malignant).
Conventionally, PSMA is detected using labelled monoclonal antibodies or small molecules [17, 18] , which indicate the expression of PSMA protein. The most prominent of the monoclonal antibodies are 7E11 (ProstaScint®) and the more recently developed J591. In 1996, the US Food and Drug Administration approved the use of ProstaScint (indium-111 [
111
In]-labelled capromab pendetide or 7E11, Cytogen Corporation, Princeton NJ, USA), for single-photon emission computed tomography (SPECT) imaging of soft-tissue (but not bone) sites of metastatic prostate cancer for pre-surgical staging or evaluation of prostatespecific antigen (PSA) relapse after radical prostatectomy. 7E11 is a murine mAb specific for an epitope on the intracellular domain of PSMA. In several studies, ProstaScint imaging displayed sensitivity of 60 %, specificity of 70 %, positive predictive value of 60 % and negative predictive value of 70 % for prostate cancer soft-tissue lesions [19] [20] [21] . However, the intracellular binding site of 111 In-7E11 is only accessible upon membrane disruption in dying or dead cells [22] . Therefore, probably because the number of available targets in the absence of membrane disruption is limited, SPECT with 111
In-7E11 has low sensitivity for viable tumour sites (62 % for lymph node metastases, 50 % for prostate bed recurrence). Furthermore,
In-capromab pendetide does not bind to viable prostate cancer sites in bone (the most common site of metastatic disease), and in contrast to PET, SPECT remains only semiquantitative in the clinical setting.
For PET, a variety of appropriate radioisotopes with different properties are available and already in clinical use. The novel PET nuclide Zirconium-89 ( 89 Zr), with its unique physical decay properties and energy (t 1/2 =78.43 h, β + =22.3 %, E β+,max = 901 keV, E γ =909 keV), is ideally suited for targeted imaging probes, especially antibodies. The greater half-life provides copious activity at the required circulation times for optimal targeting to disease sites [23, 24] . The longer half-life even enables imaging at later time points, including 120 hours post injection, an imaging window difficult to achieve with the shorter-lived PET nuclides 18 F and 64 Cu [23, 25] . Recently, a new imaging approach was described for 7E11, utilising the perceived disadvantage that the recognised epitope only becomes accessible upon membrane disruption [24] . 89 Zr was conjugated to 7E11 to provide a radiotracer for measuring the response of prostate cancer to treatment by using biodistribution studies and immunoPET imaging. It was shown that the effects of chemotherapy, chemical castration or radiotherapy could be monitored by observing 7E11 uptake, which increased with progressing cell membrane disruption resulting from treatment-induced cell death (Fig. 2) . The uptake of 89 Zr-7E11 correlated strongly with markers of cell death and apoptosis (Fig. 3) . The results confirmed that 89 Zr-7E11 immunoPET could potentially be used for successful non-invasive evaluation of treatment response regardless of the type of therapy applied [24] .
In contrast to 7E11, the humanised J591 monoclonal antibody targets the extracellular epitope of PSMA [26] , which is available on live and dead cells alike. J591 is therefore not significantly influenced by changes in membrane permeability. It has been radiolabelled with 89 Zr for immunoPET imaging where it has demonstrated high tumour-to-background tissue ratios [23] (Fig. 4) . Overall, the novel radiotracers 89 Zr-7E11 and -J591 represent promising candidates for translation to the clinic for noninvasively diagnosing prostate cancer and assessing its response to treatment. A clinical trial using J591 is currently underway (NCT01543659) as are several trials using J591 as a therapeutic agent. The radiolabelled J591 has also been used to perform targeted Cerenkov imaging in mouse models [3] . Compared to standard optical imaging approaches, Cerenkov imaging approaches using approved radiotracers offer the possibility of relatively rapid clinical translation [27] . Cerenkov radiation is produced when charged particles travel faster than the speed of light through a dielectric medium [27] . Cerenkov imaging exploits the light emission from commonly used diagnostic (e.g., all PET isotopes) and many therapeutic radionuclides [27] . This modality detects a lower amount of light compared to other optical imaging techniques such as fluorescence and bioluminescence; however, it benefits from high signal-to-noise ratios resulting from lack of incident light sources [27] .
Hormone therapy is often used in the management of prostate cancer. Wright and colleagues [28] have observed that hormone deprivation leads to an increase of PSMA expression in vitro while hormone replenishment suppresses Cu-J591) in prostate cancer xenograft models [29] . Similar findings have also been reported for PSA.
In addition to antibodies, several small molecules have been described as ligands to PSMA. Low-molecular-weight imaging agents have several inherent advantages over bigger ligands such as antibodies, including faster tumour uptake and increased clearance from non-target sites. Many low-molecularweight inhibitors of PSMA have been reported [30] [31] [32] . A prominent example -now translated to the clinic -is
, a small molecule inhibitor of PSMA's carboxypeptidase function [32] . As an inhibitor this small molecule binds specifically and irreversibly to PSMA's active side. Since tumour uptake and blood clearance are more rapid for small molecules than for antibodies, the pharmacodynamics of 18 F-DCFBC are more favourable, with higher tumour-to-background ratios; however, a moderate degree of remaining blood pool activity has been noted, possibly due to binding to serum proteins. Abnormal uptake may be noted at sites (e.g., lymph nodes) that would not be deemed metastatic based on size criteria on standard cross-sectional imaging (Fig. 5) . Similar agents have been labelled with 123 I for SPECT imaging [33] . These compounds also demonstrate rapid distribution, blood clearance rates and tumour uptake, providing very good tumour-to-background contrast (Fig. 6) . The same inhibitor has also been used for a targeted, nanoparticle-based theranostic approach [34] , combining imaging and drug delivery in one entity [35] . For targeting to PSMA, this particle carried the small molecule PSMA inhibitor; for therapy, it carried the enzyme bacterial cytosine deaminase (bCD) to convert the nontoxic pro-drug 5-fluorocytosine (5-FC) to cytotoxic 5-fluorouracil (5-FU) and a vector for siRNA to downregulate choline kinase, which is overexpressed in prostate cancer. The particle was labelled for imaging with the near-infrared fluorochrome Cy5.5 for optical imaging and In-DOTA for SPECT imaging. Multiple optical imaging agents targeting PSMA have been developed, some utilising the J591 antibody with various light emitters, including radiotracers for Cerenkov emission [3, 36] . A few small-molecule-based fluorescent agents have been developed as well, based on either phosphoramidate or ureabased peptidomimetics [17, 37] . While these agents currently remain in the pre-clinical realm (Fig. 7) , considerable efforts are underway to move them forward into clinical applications. A number of methods exist to perform whole-body tomography with fluorescent agents on animals [38] , but at present there are no methods for applying this concept to whole body human scanning. Therefore, surface-based optical imaging (mostly intraoperative and endoscopic) is being pursued [39] . Enhanced intraoperative detection of cancerous lesions has been achieved with fluorescence-guided imaging and resection, using fluorescent dyes that target tumours [39] [40] [41] . Because of superior tissue penetration and decreased autofluorescence, dyes with emission in the near-infrared (NIR) window of the spectrum (650−900 nm) are preferred.
Another promising ligand to detect PSMA is an aptamer. Aptamers are relatively short strands of oligonucleic molecules that bind to a specific target [42] . Aptamers are widely known as a substitute for antibodies, because these molecules overcome some weaknesses of antibodies. They offer high stability, facile production, low immunogenicity, rapid clearance and the possibility of binding to targets that are low in immunogenicity. An aptamer targeting PSMA (A10) has been developed [43] and has been coupled to a copolymeric drug-delivering nanoparticle; a single intratumoral administration of the construct was significantly more efficacious in tumour reduction than were non-targeted particles and controls in animal experiments [44] . Similar constructs have been made with the toxin gelonin, resulting in 600-fold higher potency on PSMA-positive cells than that achieved with negative controls [45] . Polymeric nanoparticles containing cyanine dyes as fluorochromes have been devised for fluorescence imaging [46] . Iron oxide nanoparticles coated with the aptamer and intercalated doxorubicin have been used for MR imaging and targeted drug delivery [47] . Recently, A10 has been radiolabelled with 64 Cu for possible PET imaging of PSMA-positive tumours [48] .
Prostate-specific antigen (PSA)
Standard prostate cancer screening is partially based on the detection of abnormally increased serum PSA levels; however, prostate cancers are found in up to 15 % of patients with normal serum, including aggressive tumours with Gleason scores of ≥7 [49] . PSA screening therefore cannot reliably differentiate between indolent and aggressive disease [50] . Although PSA expression is tightly coupled to androgen receptor signalling and approximately 80 % to 90 % of prostate cancers are dependent on androgens, the ability to detect PSA in serum requires not only its expression within the cells but also its secretion and leakage into the circulation [51] . Only a very small amount of PSA is secreted into perivascular space and then ultimately into the serum [52] . Importantly, PSA is initially produced as an active protease ('free' PSA), and after its release into the perivascular space, it is quickly converted to its inactive forms ('complexed' PSA) [53] . A monoclonal antibody (5A10) recognising an epitope near the catalytic cleft of PSA has been developed. This antibody only binds to free PSA, which remains associated with the tumour. Zr-labeled 5A10 has exhibited excellent tumour uptake in multiple preclinical models of prostate cancer [51] . Importantly, the androgen dependence of the PSA could be visualised with PET. In one study, therapy with increasing amounts of the anti-androgen enzalutamide demonstrated a dose-dependent depression of tumour-associated 89 Zr-5A10 in primary tumours as well as bone lesions, while testosterone supplementation resulted in increased binding [51] . This study provided more evidence that therapy-dependent molecular changes of AR-targeted prostate-specific genes -the expression levels of PSA [51] as well as PSMA [29] -can be quantified non-invasively with radiolabelled antibodies and PET. Since such tracers can be translated relatively quickly for clinical use, initial clinical trials are imminent.
Other targets
Several other targets on prostate cancer cells as well as on neovasculature of prostate cancers have been described. Prostate stem cell antigen (PSCA) is a cell surface glycoprotein, which is overexpressed in the majority of prostate cancers and prostate bone metastases. Antibodies against this antigen have been raised [54] for PET imaging, although the uptake in the tumour, at less than 5 %, was relatively low. The antigen has also been targeted with an antibody-nanoparticle construct for combined MR imaging and immunotherapy [55] or drug release [56] . Another promising target is bombesin. The gastrin-releasing peptide receptor (GRPR) provides a promising target for staging and monitoring prostate cancer, since it is overexpressed only in prostate cancer and not in normal prostatic tissue. Bombesin is a 14-amino-acid peptide with a high binding affinity and specificity to the GRPR [57] . Radiopharmaceuticals containing bombesin or its analogues, labelled with 99 mTechnetium, have been developed to target GRPR-expressing tumours for nuclear imaging, mainly with SPECT. Limited clinical studies have shown promise in detecting primary prostate cancer, nodal and bone metastases [58, 59] . Other labelling methods to obtain agents suitable for PET imaging are currently underway [60] . Fluorescently labelled versions have been evaluated in animal models [61] and could find their way into intraoperative imaging eventually.
Conclusion
Multiple molecular imaging agents for prostate cancer are currently being evaluated -most of them in preclinical settings but a few in clinical trials. In the future, quantitative radiotracers may be used not only to characterise prostate cancer and to stage disease, but also to follow molecular events during drug therapy to gauge therapeutic effectiveness much earlier. Once approved, optical imaging agents could literally lead the surgeon to the cancer and to potential areas of invasion or metastatic lymph nodes. The result may be improved surgical resection and, hopefully, better outcomes. In addition, many of the imaging agents described have been explored for therapeutic approaches as well, either as theranostic nano-agents or for simply delivering a cytotoxic agent to the tumour. The future of molecularly driven prostate cancer diagnosis and therapy appears promising.
